Addex Therapeutics Ltd
ADXN
$9.47
$0.010.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -44.18% | -- | |||
| Total Revenue | -44.18% | 4,547.06% | |||
| Cost of Revenue | 63.71% | 133.33% | |||
| Gross Profit | -153.81% | -30.12% | |||
| SG&A Expenses | 11.81% | 33.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.79% | 47.96% | |||
| Operating Income | -31.75% | -32.91% | |||
| Income Before Tax | -44.94% | -20.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -44.94% | -20.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -36.23% | -19.33% | |||
| EBIT | -31.75% | -32.91% | |||
| EBITDA | -31.83% | -39.91% | |||
| EPS Basic | -32.93% | -19.29% | |||
| Normalized Basic EPS | -42.31% | -20.93% | |||
| EPS Diluted | -32.93% | -19.29% | |||
| Normalized Diluted EPS | -42.31% | -20.93% | |||
| Average Basic Shares Outstanding | 2.21% | 0.01% | |||
| Average Diluted Shares Outstanding | 2.21% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||